Citigroup
MYGN icon

Citigroup’s Myriad Genetics MYGN Stock Holding History

Citigroup’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-47,200
Closed -$933K – 7002
2020
Q4 		$933K Buy
47,200
+1,400
+3% +$22.6K ﹤0.01% 3603
2020
Q3 		$597K Sell
45,800
-35,800
-44% -$453K ﹤0.01% 3707
2020
Q2 		$925K Sell
81,600
-26,900
-25% -$382K ﹤0.01% 3633
2020
Q1 		$1.55M Buy
108,500
+17,200
+19% +$363K ﹤0.01% 2738
2019
Q4 		$2.49M Buy
91,300
+83,800
+1,117% +$2.31M ﹤0.01% 2760
2019
Q3 		$215K Sell
7,500
-3,600
-32% -$105K ﹤0.01% 5093
2019
Q2 		$308K Buy
11,100
+6,900
+164% +$195K ﹤0.01% 4894
2019
Q1 		$140K Buy
4,200
+2,900
+223% +$88.3K ﹤0.01% 5438
2018
Q4 		$38K Sell
1,300
-2,600
-67% -$93.5K ﹤0.01% 6451
2018
Q3 		$179K Buy
3,900
+2,600
+200% +$116K ﹤0.01% 5369
2018
Q2 		$49K Buy
+1,300
New +$43.9K ﹤0.01% 6303
2018
Q1 		– Sell
-1,300
Closed -$45K – 7619
2017
Q4 		$45K Sell
1,300
-49,600
-97% -$1.67M ﹤0.01% 6253
2017
Q3 		$1.84M Buy
50,900
+45,000
+763% +$1.28M ﹤0.01% 2739
2017
Q2 		$152K Sell
5,900
-1,600
-21% -$34K ﹤0.01% 5017
2017
Q1 		$144K Buy
7,500
+4,700
+168% +$83.3K ﹤0.01% 4931
2016
Q4 		$47K Sell
2,800
-300
-10% -$5.43K ﹤0.01% 6174
2016
Q3 		$64K Buy
3,100
+2,600
+520% +$65.9K ﹤0.01% 5503
2016
Q2 		$15K Buy
+500
New +$17.4K ﹤0.01% 6319
2016
Q1 		– Sell
-200
Closed -$9K – 7646
2015
Q4 		$9K Sell
200
-1,300
-87% -$54.9K ﹤0.01% 6861
2015
Q3 		$56K Buy
1,500
+1,400
+1,400% +$49.7K ﹤0.01% 5366
2015
Q2 		$3K Buy
+100
New +$3.4K ﹤0.01% 6998

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup's MYGN Position: Q2 2026 in Review

Citigroup increased its Myriad Genetics (MYGN) stake by 587% in Q2 2026, buying an estimated $453K and bringing the position to 116,820 shares worth $667K. The position accounts for ﹤0.01% of the portfolio, ranked #3742.

Citigroup first reported a position in MYGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $6.58M in Q4 2018. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Citigroup held 116,820 shares of Myriad Genetics worth $667K as of Q2 2026.
  • Citigroup bought 99,813 Myriad Genetics shares in Q2 2026, an estimated $453K.
  • Myriad Genetics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3742 holding.
  • Citigroup first reported a position in Myriad Genetics in Q2 2013 and has held it in 53 quarters since.
  • Citigroup's Myriad Genetics position peaked at $6.58M in Q4 2018.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.